Please login to the form below

Not currently logged in

Roche’s Torsten Hoffmann to join Zealand Pharma

Joins the Danish biotech as chief scientific officer

Zealand Pharma Torsten Hoffmann Dr Torsten Hoffmann has left his senior role at pharma company Roche to join the Danish biotech Zealand Pharma as chief scientific officer.

Dr Hoffmann (pictured) was head of head of discovery chemistry, pharma research, at Roche – a role he'd held since 2005.

He initially joined the company in 1997 as a laboratory head before working his way up the ranks in early-stage science, and was responsible for the identification of more than 25 drug candidates that entered clinical development.

In his new role at Zealand, Dr Hoffmann joins a more compact company focused on the discovery of drugs in cardio-metabolic diseases, diabetes and obesity.

Its lead product is the GLP-1 agonist lixisenatide, which is licensed to Sanofi who markets it as Lyxumia for the treatment of type 2 diabetes.

"These are exciting times for the company following the launch of its first discovered medicine,” commented Dr Hoffmann.

As chief scientific officer, Dr Hoffmann will be expected to further drive innovation and strengthen Zealn's research efforts, which includes collaborations with Boehringer Ingelheim and Lilly.

“Torsten is known for being a strong and collaborative leader and his impressive and impactful scientific record plus wealth of sector experience and innovative ideas will be extremely valuable to our company,” said Zealand's CEO David Solomon.

“I am confident that under his leadership, we can drive Zealand's R&D activities further towards tomorrow's breakthrough peptide therapeutics.”

4th September 2013


Featured jobs

Subscribe to our email news alerts


Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...
figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...